ALPANA Ventures

Resistell publishes an article in Nature Communications

Resistell, a portfolio company of Alpana Ventures, in collaboration with University Hospital Lausanne (CHUV) in Switzerland, the University Hospital Ramón y Cajal in Madrid, Spain and the Medical University of Innsbruck, Austria, has published an article in Nature Communications: « Accurate and rapid antibiotic susceptibility testing using a machine learning-assisted nanomotion technology platform » 

Resistell Nature Communications Press Release March 2024

The research was supported by grants:

  • the European Union’s Accelerator grant RAPID-SEP-AST 961141
  • Innosuisse Swiss Agency for the Promotion of Innovation grant 36334.1 IP-LS
  • Swiss National Science Foundation (SNSF) grant CRSII5_173863
  • Pfizer grant for ceftazidime-avibactam project


and Resistell’s investors: 

  • Alpana Ventures
  • Trumpf Venture
  • Occident Group
  • Zürcher Kantonalbank (ZKB) 
  • EIC Fund
  • Venture Kick
  • and other investors


Read the article